tiprankstipranks
Jinhai International Group Holdings Limited (HK:2225)
:2225
Hong Kong Market

Jinhai International Group Holdings Limited (2225) AI Stock Analysis

1 Followers

Top Page

HK:2225

Jinhai International Group Holdings Limited

(2225)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 5.2)
Rating:53Neutral
Price Target:
HK$2.00
▲(61.29% Upside)
Action:ReiteratedDate:01/31/26
The score is held back primarily by weak financial performance (losses, deteriorating profitability, and negative cash flows). Technicals are supportive with an established uptrend and positive MACD, but overbought signals add risk. Valuation also weighs on the score due to ongoing losses (negative P/E) and no dividend support.
Positive Factors
Diversified business model
Multiple business lines (manufacturing, trading, logistics, property) provide durable revenue diversification and reduce reliance on a single market cycle. Over months this supports resilience to sector-specific shocks, cross-selling, and smoother cash flows versus single-segment peers.
Negative Factors
Sharp revenue decline
A steep year-over-year revenue decline signals weakening demand or lost market share, eroding operating leverage. Sustained top-line contraction can depress margins, limit reinvestment, and impair the firm's ability to fund growth or stabilize earnings in the coming 2-6 months.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model
Multiple business lines (manufacturing, trading, logistics, property) provide durable revenue diversification and reduce reliance on a single market cycle. Over months this supports resilience to sector-specific shocks, cross-selling, and smoother cash flows versus single-segment peers.
Read all positive factors

Jinhai International Group Holdings Limited (2225) vs. iShares MSCI Hong Kong ETF (EWH)

Jinhai International Group Holdings Limited Business Overview & Revenue Model

Company Description
Jinhai Medical Technology Ltd. provides manpower outsourcing and ancillary services. It offers services to the building and construction contractors also provides dormitory, warehousing, cleaning, and building maintenance services. The company was...
How the Company Makes Money
Jinhai International Group Holdings Limited generates revenue through multiple streams. Its core revenue comes from the manufacturing and sale of consumer goods, particularly electronics and textiles, which are distributed both domestically and in...

Jinhai International Group Holdings Limited Financial Statement Overview

Summary
Weak fundamentals: declining revenue growth, net losses and negative margins (EBIT/EBITDA), plus negative operating cash flow and free cash flow. Leverage appears manageable, but negative ROE and cash conversion issues keep the score low.
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue38.83M50.24M45.64M22.28M21.90M22.47M
Gross Profit6.14M11.48M12.03M10.12M7.73M8.85M
EBITDA-20.18M-16.82M1.11M5.25M5.44M2.15M
Net Income-22.18M-17.96M-3.14M468.00K-246.21K1.26M
Balance Sheet
Total Assets50.15M58.87M62.22M40.27M33.77M39.41M
Cash, Cash Equivalents and Short-Term Investments6.97M14.93M26.76M23.95M25.91M27.39M
Total Debt14.67M14.52M10.08M4.45M1.87M5.50M
Total Liabilities22.38M26.09M24.73M15.68M9.75M13.92M
Stockholders Equity27.36M31.81M37.47M24.37M24.28M25.49M
Cash Flow
Free Cash Flow-4.86M-4.26M-3.15M3.06M2.73M7.25M
Operating Cash Flow-4.10M-3.25M-1.91M4.24M3.34M7.38M
Investing Cash Flow-1.63M-9.22M-6.51M-1.15M-2.64M-6.04M
Financing Cash Flow3.11M2.93M13.62M-3.72M-4.81M-4.15M

Jinhai International Group Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.24
Price Trends
50DMA
2.01
Positive
100DMA
1.64
Positive
200DMA
1.42
Positive
Market Momentum
MACD
0.07
Negative
RSI
57.43
Neutral
STOCH
65.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2225, the sentiment is Positive. The current price of 1.24 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.01, and below the 200-day MA of 1.42, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 57.43 is Neutral, neither overbought nor oversold. The STOCH value of 65.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2225.

Jinhai International Group Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
HK$1.42B10.335.63%-10.48%30250.00%
70
Outperform
HK$1.12B3.2610.96%36.73%17.49%9.67%
70
Outperform
HK$131.55M-10.871.60%
66
Neutral
HK$45.60M463.707.29%-11.47%5.00%
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
53
Neutral
HK$11.69B-63.97-43.42%-33.94%-119.13%
43
Neutral
HK$630.54M2.51-4.24%2.26%14.29%-200.37%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2225
Jinhai International Group Holdings Limited
2.21
0.92
71.32%
HK:2180
ManpowerGroup Greater China Limited
5.41
2.35
76.80%
HK:6100
Tongdao Liepin Group
2.79
-0.60
-17.70%
HK:6919
Renrui Human Resources Technology Holdings Limited
4.12
0.31
8.14%
HK:8031
ETS Group Limited
0.45
0.26
134.21%
HK:8462
Omnibridge Holdings Ltd.
0.08
>-0.01
-7.32%

Jinhai International Group Holdings Limited Corporate Events

Jinhai Medical Technology Announces Resignation of Non-Executive Director and Vice-Chairman
Jan 29, 2026
Jinhai Medical Technology Limited has announced that non-executive director and vice-chairman of the board, Mr. Jiang Jiangyu, has resigned with effect from 29 January 2026 due to other business commitments requiring more of his time. The company ...
Jinhai Medical Technology Updates Board and Committee Structure
Jan 29, 2026
Jinhai Medical Technology Limited has updated its board composition effective 29 January 2026, confirming a structure that includes three executive directors led by Chairman Chen Guobao and CEO Wang Zhenfei, one non-executive director, and three i...
Jinhai Medical Technology Relocates Hong Kong Office
Nov 18, 2025
Jinhai Medical Technology Limited has announced a change in its principal place of business in Hong Kong, effective from November 19, 2025. The relocation to Chinachem Century Tower in Wanchai signifies a strategic move that could enhance its oper...
Jinhai Medical Technology Partners with Medtronic Changzhou for Spinal Endoscopy Advancement
Nov 6, 2025
Jinhai Medical Technology Limited announced a strategic cooperation framework agreement with Medtronic Changzhou to promote real-time navigation and tracking spinal endoscope techniques in the PRC. This collaboration aims to develop advanced integ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 31, 2026